CSF1R and tenosynovial giant cell tumor, diffuse type: Finally, CSF1/CSF1R-targeting agents have demonstrated a favorable safety profile and potent blocking activity, particularly in diffuse-type tenosynovial giant cell tumors (TGCT) (304).